News - NLSDays - NLSDays

Latest news in cooperation with Nordic Life Science

In focus – U.S. drug prices

21 February 2019 | 12:43 pm

The stories have been in the U.S. media over and over in the past few years – the cost of a life-saving or maintenance drug suddenly jumps by as much as 1 000 percent, leaving patients and their advocates angry and bewildered. Less dramatic are the ongoing reports of Americans, especially the elderly, struggling to […]

Lundbeck increases its share capital

20 February 2019 | 8:20 am

The company has decided to increase its share capital by DKK 28,155 as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 3,795 […]

Novo Nordisk receives FDA approval

20 February 2019 | 8:13 am

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Biologics License Application for ESPEROCT for the treatment of adults and children with haemophilia A. ESPEROCT is the brand name for turoctocog alfa pegol, N8-GP. It is indicated for use in adults and children with haemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce […]

Spago Nanomedical initiates clinical trial

20 February 2019 | 8:07 am

The company has received approval from the Swedish Medical Products Agency to initiate the first clinical trial with the contrast agent SpagoPix (SN132D) in patients with breast cancer. SpagoPix is a nanomedical contrast agent with potential to improve cancer diagnostics with magnetic resonance imaging (MRI). ”SN132D is a new and interesting contrast agent for MRI […]

Vaccibody secures NOK 230 million

18 February 2019 | 5:21 am

The company announces that a Private Placement has been successfully placed, raising gross proceeds of NOK 230 million by allocating 5,750,000 shares at a subscription price of NOK 40.00 per Offer Share. The Private Placement received strong interest from existing shareholders and new investors. The net proceeds from the Private Placement will i.a. be used […]

Positive results from Orion trial

18 February 2019 | 4:28 am

Orion’s and Bayer’s darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial. First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium and simultaneously published in The […]

Phase III data from Lundbeck did not meet the primary endpoint

14 February 2019 | 12:30 pm

Lundbeck and Otsuka report new data from their trials evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder. Data from two global Phase III clinical trials evaluating the safety and efficacy of brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder did not meet the primary […]

Fighting antibiotic resistance by strengthening our immune defences

14 February 2019 | 8:58 am

I began to be interested in the problem of antibiotic resistance almost 30 years ago. A couple of colleagues and I were evaluating some patent applications describing the possibilities of replacing antibiotics in animal feed with lactobacillus. At that time, similarly to today, antibiotics were routinely used to stimulate the growth of animals raised for […]

AstraZeneca closed 2018 with a strong quarter

14 February 2019 | 8:19 am

The pharma company has announced its full-year and Q4 2018 results and new launches and commercial execution delivered full-year sales growth and a very strong final quarter. The final quarter of the year saw a very strong performance, including Product Sales growth of 5% (8% at CER) to $5,768m, according ot the RNS, the news […]

Unique opportunity to lease a modern life science property

13 February 2019 | 12:52 pm

Latest news in cooperation with Nordic Life Science

In focus – U.S. drug prices

Lundbeck increases its share capital

Novo Nordisk receives FDA approval

Spago Nanomedical initiates clinical trial

Vaccibody secures NOK 230 million

Positive results from Orion trial

Phase III data from Lundbeck did not meet the primary endpoint

Fighting antibiotic resistance by strengthening our immune defences

AstraZeneca closed 2018 with a strong quarter

Unique opportunity to lease a modern life science property

Join the conference!

Join the conference!

© 2019 Bionordic. All Rights Reserved
Legal Notices

Latest news in cooperation with Nordic Life Science

Join the conference!

© 2019 Bionordic. All Rights ReservedLegal Notices

© 2019 Bionordic. All Rights Reserved
Legal Notices